Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
LungenClinic Grosshansdorf · Boehringer Ingelheim (Germany) · +10 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
945
total citations
- FWCI
- 88.95
- Percentile
- 100%
- References
- 37
Citations per year
Authors
14Topics & keywords
Topics
Keywords
- Docetaxel
- Nintedanib
- Medicine
- Placebo
- Lung cancer
- Oncology
- Internal medicine
- Double blind
No related works found for this paper.